SCHEMBL24185272

SCHEMBL24185272

N#CC1CN(C(=O)c2ccc(Br)cc2)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.54
▸ MGLL Q99685 1/20 0.48
▸ HSD11B1 P28845 1/20 0.48
▸ L3MBTL3 Q96JM7 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ TLR2 O60603 1/20 0.47
▸ TLR1 Q15399 1/20 0.47
▸ POLB P06746 2/20 0.45
▸ CA12 O43570 1/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ CA7 P43166 1/20 0.45
▸ CA9 Q16790 1/20 0.45
▸ CA14 Q9ULX7 1/20 0.45
▸ GPR183 P32249 2/20 0.45
▸ JAK2 O60674 1/20 0.43
▸ JAK1 P23458 1/20 0.43
▸ JAK3 P52333 1/20 0.43
▸ KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24185211 0.83 MGLL (0.48) HPGDMGLLL3MBTL3L3MBTL1ALDH1A1
SCHEMBL22854291 0.80 ALDH1A1 (0.56) MGLLL3MBTL1ALDH1A1POLBJAK2
SCHEMBL20335412 0.79 HPGD (0.61) HPGDMGLLHSD11B1L3MBTL3L3MBTL1
SCHEMBL2131094 0.77 HPGD (0.59) HPGDMGLLHSD11B1L3MBTL3L3MBTL1
SCHEMBL8371894 0.77 HPGD (0.59) HPGDMGLLHSD11B1L3MBTL3L3MBTL1
SCHEMBL3454938 0.75 GAA (0.68) HPGDL3MBTL3L3MBTL1ALDH1A1TLR2
SCHEMBL5967832 0.75 GAA (0.68) HPGDL3MBTL3L3MBTL1ALDH1A1TLR2
SCHEMBL26773757 0.74 RAB9A (0.53) HPGDL3MBTL1ALDH1A1JAK2JAK1
SCHEMBL24340054 0.73 NPC1 (0.69) HPGDALDH1A1POLBKMT2ALMNA
SCHEMBL24691415 0.73 NPC1 (0.69) HPGDALDH1A1POLBKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2023-11-23 — — US disclosed
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2023-11-23 — — US disclosed
WO-2022011337-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2022-01-13 — — WO disclosed
WO-2022011338-A2 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2022-01-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF TYK2, MAPKAPK2, MAP3K20 HPGD 4226/4885MGLL 3645/4885HSD11B1 4378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback